Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a note issued to investors on Tuesday. The brokerage set a "hold" rating on the medical research company's stock.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Cytosorbents presently has an average rating of "Moderate Buy" and a consensus target price of $4.67.

Cytosorbents Stock Performance

CTSO stock traded down $0.00 during midday trading on Tuesday, reaching $1.10. 17,054 shares of the company's stock traded hands, compared to its average volume of 145,136. The firm has a market capitalization of $60.09 million, a PE ratio of -3.04 and a beta of 0.78. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The company has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.05. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Remove Ads

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in shares of Cytosorbents during the 4th quarter worth $30,000. Northern Trust Corp increased its holdings in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the last quarter. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% in the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after buying an additional 118,387 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents during the 4th quarter worth about $99,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after purchasing an additional 8,400 shares during the period. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.